Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter.
Relmada Therapeutics Trading Up 7.7 %
Shares of NASDAQ:RLMD opened at $0.29 on Monday. Relmada Therapeutics has a 1 year low of $0.24 and a 1 year high of $5.84. The business has a fifty day simple moving average of $0.34 and a 200 day simple moving average of $1.75. The firm has a market cap of $8.83 million, a price-to-earnings ratio of -0.10 and a beta of 0.65.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Leerink Partnrs lowered Relmada Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 4th. Leerink Partners reiterated a “market perform” rating and set a $1.00 price objective (down from $10.00) on shares of Relmada Therapeutics in a report on Wednesday, December 4th. Finally, Mizuho reiterated a “neutral” rating and set a $1.00 price objective (down from $23.00) on shares of Relmada Therapeutics in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.25.
Relmada Therapeutics Company Profile
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Stories
- Five stocks we like better than Relmada Therapeutics
- How to Use the MarketBeat Stock Screener
- How to Build the Ultimate Everything ETF Portfolio
- Health Care Stocks Explained: Why You Might Want to Invest
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.